% | $
Quotes you view appear here for quick access.

ONYX Pharmaceuticals, AŞ Message Board

  • bearofbleecker bearofbleecker Apr 5, 2013 4:29 PM Flag

    Note on International MM Workshop

    Looking at the press release in the Onyx website, I see that the only "new data" to be presented in Kyota are for trials of opromozib in hematological malignancies. (This presentation has already taken place, I think. We might recall that there were a lot of hints in the last CC that they place a lot of importance on this oral proteasome inhibitor.) For Kyrpolis, their major presentation is a study of Kyrpolis in combination with Revlimid and low-dose dexamethasone in high-risk smoldering myeloma in the elderly. This is moving Kyrpolis way up in the order of battle. I imagine that these patients, being elderly, are not candidates for stem cell transplants and therefore the various treatment cycles (Velcade, chemotherapy, etc.) which precede it. The theory here, I gather, would be to throw the three least noxious drugs at them in combination to see if this will slow their progression to fullblown MM.

    SortNewest  |  Oldest  |  Most Replied Expand all replies